Joint Session of the ESR and EORTC

ESR/EORTC - Current status of breast cancer imaging in clinical trials

March 1, 16:00 - 17:30 CET

5 min
Chairperson's introduction
25 min
Oligometastatic breast cancer screening in clinical trials
  1. To learn which imaging modalities provide a more accurate diagnosis of oligometastatic disease.
  2. To become familiar with the current guidelines.
  3. To understand the use of modern imaging modalities in oligometastatic breast cancer.
25 min
New imaging technologies for advanced breast cancer
  1. To highlight the value of whole-body MRI as a highly accurate modern imaging tool for metastatic screening in breast cancer.
  2. To illustrate the specific indications of WB-MRI in advanced breast cancer, from diagnosis of metastasis to response assessment.
  3. To understand the respective roles of WB-MRI and PET/CT and how a patient-specific approach to metastatic disease is currently necessary.
25 min
Optimal use of FDG-PET/CT in breast cancer: new EANM/SNMMI guidelines, endorsed by ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA
  1. To learn about the evidence-based recommendations to perform 2-[18F]FDG PET/CT in the initial staging, in assessing response to therapy and in assessing recurrence.
  2. To become familiar with the new guidelines.
  3. To understand the role of 2-[18F]FDG-PET/CT in NST breast cancer.
10 min
Panel discussion